Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Cambridge's Enumeral Filed for Bankruptcy, Sells Assets to Bay Area's XOMA

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:BioPharma

It's the end of the road for Cambridge, MA based Enumeral Biomedical. Source: BioSpace

Continue ReadingCambridge's Enumeral Filed for Bankruptcy, Sells Assets to Bay Area's XOMA

Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:BioPharma

Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace

Continue ReadingBiogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop

GlaxoSmithKline's Booming Pipeline Under CEO Emma Walmsley

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:BioPharma

Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical. Source: BioSpace

Continue ReadingGlaxoSmithKline's Booming Pipeline Under CEO Emma Walmsley

Another Day, Another Breakthrough Tag for GlaxoSmithKline's Bexsero

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:BioPharma

Bexsero is the first vaccine in the world to receive the designation twice. Source: BioSpace

Continue ReadingAnother Day, Another Breakthrough Tag for GlaxoSmithKline's Bexsero

Gottlieb Flags New Approaches to Opioids, Drug Pricing, Internal Challenges

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:Drug Industry Daily

FDA Commissioner Scott Gottlieb offered an update on the agency’s plans to address the opioid epidemic, encourage market competition, and tackle internal agency issues, in remarks Tuesday to the Alliance…

Continue ReadingGottlieb Flags New Approaches to Opioids, Drug Pricing, Internal Challenges

Federal Circuit Affirms Dismissal of AbbVie Lawsuit in MedImmune Patent Dispute

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:Drug Industry Daily

The Federal Circuit backed up a lower court ruling dismissing an AbbVie lawsuit seeking to invalidate a patent it licensed from MedImmune. Source: Drug Industry Daily

Continue ReadingFederal Circuit Affirms Dismissal of AbbVie Lawsuit in MedImmune Patent Dispute

Penalties for Drug Falsification Vary Widely Between EU Members

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:Drug Industry Daily

Punishments for falsification of medicines in the European Union vary significantly between EU member states, according to a study carried out for the European Commission. Source: Drug Industry Daily

Continue ReadingPenalties for Drug Falsification Vary Widely Between EU Members

TGA Issues Risk Survey to Drugmakers Ahead of First Pharmacovigilance Inspections

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:Drug Industry Daily

Australia’s Therapeutic Goods Administration issued a survey to drugmakers asking about their pharmacovigilance activities with the intention of using the responses to prioritize inspections. Source: Drug Industry Daily

Continue ReadingTGA Issues Risk Survey to Drugmakers Ahead of First Pharmacovigilance Inspections

EMA Prevails Against Drugmakers Seeking to Block Release of Clinical Trial Data

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:Drug Industry Daily

A European Union court ruled that the European Medicines Agency can offer access to clinical trial data in a blow to three drugmakers who argued this would hurt their business.…

Continue ReadingEMA Prevails Against Drugmakers Seeking to Block Release of Clinical Trial Data

Celltrion Warned for Aseptic Practices, Training and Complaint Handling

  • Post author:Sam
  • Post published:February 6, 2018
  • Post category:Drug Industry Daily

The FDA flagged a problem with contaminated vial stoppers in a warning letter to Celltrion over deficiencies at its Incheon, South Korea facility, which manufactures Inflectra (infliximab-dyyb), the Ramicade biosimilar.…

Continue ReadingCelltrion Warned for Aseptic Practices, Training and Complaint Handling
  • Go to the previous page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company